Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00666939 |
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Condition | Intervention | Phase |
---|---|---|
Transient Insomnia |
Drug: Gabapentin Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study Of Gabapentin 100 mg and 250 mg in Transient Insomnia Induced By A Sleep Phase Advance |
Enrollment: | 773 |
Study Start Date: | October 2004 |
Study Completion Date: | January 2005 |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: Gabapentin
Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
|
B: Experimental |
Drug: Gabapentin
Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
|
C: Placebo Comparator |
Drug: Placebo
Matched placebo 30 minutes prior to bedtime
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
San Diego, California, United States, 92108 | |
United States, Florida | |
Pfizer Investigational Site | |
Ocala, Florida, United States, 34471 | |
United States, Georgia | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30328 | |
United States, Louisiana | |
Pfizer Investigational Site | |
Metairie, Louisiana, United States, 70001 | |
United States, New York | |
Pfizer Investigational Site | |
New York, New York, United States, 10025 | |
Pfizer Investigational Site | |
Thornwood, New York, United States, 10594 | |
United States, North Carolina | |
Pfizer Investigational Site | |
Raleigh, North Carolina, United States, 27612 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Duncansville, Pennsylvania, United States, 16635 | |
Pfizer Investigational Site | |
Johnstown, Pennsylvania, United States, 15904 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A9451141 |
Study First Received: | April 23, 2008 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00666939 |
Health Authority: | United States: Food and Drug Administration |
Sleep Initiation and Maintenance Disorders Excitatory Amino Acids Calcium, Dietary Gabapentin |
Mental Disorders Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Antiparkinson Agents Calcium Channel Blockers Excitatory Amino Acid Agents Cardiovascular Agents |
Antimanic Agents Pharmacologic Actions Membrane Transport Modulators Sensory System Agents Therapeutic Uses Anti-Anxiety Agents Analgesics Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants Excitatory Amino Acid Antagonists |